All lobbying filings
MADRIGAL PHARMACEUTICALS, INC.
MADRIGAL PHARMACEUTICALS, INC. filed a Q3 report for MADRIGAL PHARMACEUTICALS, INC. on October 19, 2026.
Lobbying for MADRIGAL PHARMACEUTICALS, INC. · Biopharmaceutical company
Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 19, 2026
Expenses
$350,000
What this organization spent lobbying with its own staff.
Reported using the LDA's own definitions (method A): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
Pennsylvania
Government bodies contacted
2
Lobbying activity
2
Issues related to CMMI drug pricing; 340B drug pricing
Most Favored Nation drug pricing; Issues related to CMMI drug pricing